210results about How to "Low effective dose" patented technology

The present invention is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The invention discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.

The present invention relates to control of pest infestation by inhibiting one or more biological functions. The invention provides methods and compositions for such control. By feeding one or more recombinant double stranded RNA molecules provided by the invention to the pest, a reduction in pest infestation is obtained through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.

The invention is intended for a treatment of severe infections using an injectable drug-delivery system comprising nanoparticles of a biodegradable polymer with incorporated antibacterial drug.

A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.

The present invention relates to methods for intradermally delivering one or more biologically active agents such as vaccines and therapeutic agents into the dermis layer of the skin of a subject to obtain systemic delivery or an immune response using a microneedle drug delivery device containing the agent to be delivered. The methods employ a microneedle device with a row of hollow microneedles. The microneedles penetrate the skin of the subject and assume an anchored state in which the microneedles are anchored in the skin and project laterally from the device. A pivotal motion is then performed with the device so that the skin in which the microneedles are engaged is lifted above the initial plane of the surface of the skin while the biologically active agent is delivered. The methods of the invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery routes, facilitating dose sparing.

A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.

A bioresorbable material is incorporated with bioactive agents to form an implant used for treatment against hard tissue or soft tissue defects and diseases. Antibiotics or anti-cancer agents are incorporated to treat hard or soft tissue infections or cancers. Sustained release of the bioactive agents or drug molecules may be achieved after implantation at the targeted sites. The dosage of the active agents or molecules, the microstructure, morphology, and composition of the bioresorbable material allow control of the release profile. The invented implant may be used for drug delivery, chemotherapy, or gene therapy. Various microstructure and the morphologies of the implants are injectable like putty or shaped with multilayers.

A decoy inactive carrier composition is administered simultaneously with a targeted composition containing vehicles for delivering a desired agent to a biological target. This simultaneous administration enhances the delivery of the targeted composition to the desired location in a subject.

The present invention is directed to a powdered formulation comprising an analgesic, preferably fentanyl, for use in pulmonary inhalation administration for the rapid analgesic titration of pain, in particular breakthrough pain. Upon administration, the powdered formulation is able to provide a narrower titration range in patients suffering from pain, as well as effective analgesic amounts of fentanyl in a shorter time and at lower dose levels of administered fentanyl when compared to fentanyl administered by an oral transmucosal route.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

The present invention relates to a new-type high-effective safety medicine-ginkgo leaf total lactone for curing depression. It is a terpene lactone extracted from ginkgo biloba. L or other portions of said plant, such as ginkgo nut, ginkgo root bark and ginkgo twing, in which five terpene lactone compounds of bilobalide A, bilobalide B, bilobalide C, bilobalide J and bilobalide are mainly contained.

An application of the casticin extracted from shrub chastetree fruit in preparing the medicines for preventing, diagnosing and treating premenstrual syndrome is disclosed.

The invention relates to a Chinese traditional medicine extract for preventing and treating osteoporosis and its preparation method and application. The extract mainly comprises rhizoma atractylodis volatile oil, total alkaloid of Phellodendron amurense, and total saponins of radix achyranthis bidentatae and total sterone of radix achyranthis bidentatae; can be used for preventing and/or treating osteoporosis and relevant disorder, which has gradually become important pathogenesis influencing life-quality. The extract has easily-accessible raw materials, simple preparation, high extraction efficiency, strong pharmacological action, stable quality, high safety, low toxicity, and controllable quality. The invention comprises three Chinese traditional medicines in classical prescription, come to optima activity for resisting osteoporosis, reduces adverse side effect, and provides a new medicament source for preventing, diagnostic ting, detecting, protecting, treating and researching these diseases and their relevant diseases.

The invention provides a honeysuckle extract and a preparation method for extracting chlorogenci acid. The method has the advantages of good repeatability and good stability; by using the method, the content of an active component can be improved, a large amount of impurities are removed, raw materials are high in yield and low in cost; and the method is suitable for industrial production. The percentage of the main active component chlorogenci acid in the honeysuckle extract is 30%. The preparation process of the honeysuckle extract comprises the following steps: adding water the volume of which is 8-20 times as large as that of taken honeysuckle medicinal material in the taken honeysuckle medicinal to extract for 2-4 times for 0.5-1.5 hours each time; regulating the pH value of the extract to 1-6; and on a large pore absorption resin column, eluting impurities with water firstly, then eluting with 10-70% ethanol, colleting ethanol eluent, recovering the ethanol, concentrating, regulating the pH value of a concentrated liquid to 1-6, adding ethyl acetate for extraction, recovering the ethyl acetate, concentrating and drying. By using the method, the content of the active component in the extract is improved, the curative effect is improved, a large amount of impurities are removed, the problem of large moisture absorption commonly occurring in Chinese patent medicines is solved, and side effects are reduced.